DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zioptan (Tafluprost) - Summary



Tafluprost is a fluorinated analog of prostaglandin F2-alpha.

ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

See all Zioptan indications & dosage >>


Published Studies Related to Zioptan (Tafluprost)

[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study]. [Article in Japanese] [2010]
CONCLUSION: These results indicate that Tafluprost is clinically useful in the

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. [2010]
open-angle glaucoma or ocular hypertension... CONCLUSIONS: Tafluprost is a new effective and well-tolerated treatment for

A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. [2010]
exfoliation glaucoma, or ocular hypertension... CONCLUSIONS: Tafluprost and latanoprost have comparable effects on the extent,

Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. [2009]
hypertension, uncontrolled by timolol monotherapy... CONCLUSIONS: As adjunctive therapy to timolol, tafluprost achieved a consistently

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. [2008]
analogue with a preservative-free formulation... CONCLUSIONS: THE reduction in IOP achieved by preservative-free tafluprost is

more studies >>

Clinical Trials Related to Zioptan (Tafluprost)

The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma [Recruiting]
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0. 005% eye drops (Xalatan®) and after the switch to preservative-free prostaglandin analog tafluprost 0. 0015% eye drops (Taflotan®). Patients who have been using latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost 0. 005% eye drops to the assigned preservative-free tafluprost 0. 0015% eye drops for twelve (12) months.

Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies [Recruiting]
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study will enroll patients who have ocular hypertension or glaucoma and who are using timolol or prostaglandin.

The study medication period is 6 months, but the primary evaluation of efficacy is done at 3 months.

Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002 AM1) [Recruiting]
This study will evaluate whether Preservative-Free tafluprost is non-inferior to Preservative-Free timolol in reducing intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

more trials >>

Reports of Suspected Zioptan (Tafluprost) Side Effects

Ocular Hyperaemia (8)Drug Ineffective (4)Eye Irritation (4)Growth of Eyelashes (4)Cough (4)Eye Pruritus (4)Eye Pain (4)Nasopharyngitis (3)Headache (3)Urinary Tract Infection (3)more >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015